The JAK-STAT pathway: impact on human disease and therapeutic intervention
- PMID: 25587654
- PMCID: PMC5634336
- DOI: 10.1146/annurev-med-051113-024537
The JAK-STAT pathway: impact on human disease and therapeutic intervention
Abstract
The Janus kinase (JAK)-signal transducer of activators of transcription (STAT) pathway is now recognized as an evolutionarily conserved signaling pathway employed by diverse cytokines, interferons, growth factors, and related molecules. This pathway provides an elegant and remarkably straightforward mechanism whereby extracellular factors control gene expression. It thus serves as a fundamental paradigm for how cells sense environmental cues and interpret these signals to regulate cell growth and differentiation. Genetic mutations and polymorphisms are functionally relevant to a variety of human diseases, especially cancer and immune-related conditions. The clinical relevance of the pathway has been confirmed by the emergence of a new class of therapeutics that _targets JAKs.
Keywords: autoimmunity; cancer; cytokine; immunodeficiency; kinase inhibitors.
Figures
Similar articles
-
JAKs and STATs in immunity, immunodeficiency, and cancer.N Engl J Med. 2013 Jan 10;368(2):161-70. doi: 10.1056/NEJMra1202117. N Engl J Med. 2013. PMID: 23301733 Free PMC article. Review. No abstract available.
-
JAK/STAT disruption induces immuno-deficiency: Rationale for the development of JAK inhibitors as immunosuppressive drugs.Mol Cell Endocrinol. 2017 Aug 15;451:88-96. doi: 10.1016/j.mce.2017.01.035. Epub 2017 Jan 25. Mol Cell Endocrinol. 2017. PMID: 28131742 Review.
-
_targeting the JAK-STAT pathway in autoimmune diseases and cancers: A focus on molecular mechanisms and therapeutic potential.Biochem Pharmacol. 2021 Nov;193:114760. doi: 10.1016/j.bcp.2021.114760. Epub 2021 Sep 4. Biochem Pharmacol. 2021. PMID: 34492272 Review.
-
Inborn errors of human JAKs and STATs.Immunity. 2012 Apr 20;36(4):515-28. doi: 10.1016/j.immuni.2012.03.016. Immunity. 2012. PMID: 22520845 Free PMC article. Review.
-
The JAK/STAT signaling pathway: from bench to clinic.Signal Transduct _target Ther. 2021 Nov 26;6(1):402. doi: 10.1038/s41392-021-00791-1. Signal Transduct _target Ther. 2021. PMID: 34824210 Free PMC article. Review.
Cited by
-
JAK inhibitors: an evidence-based choice of the most appropriate molecule.Front Pharmacol. 2024 Oct 29;15:1494901. doi: 10.3389/fphar.2024.1494901. eCollection 2024. Front Pharmacol. 2024. PMID: 39559737 Free PMC article. Review.
-
Cirsilineol improves anesthesia/surgery-induced postoperative cognitive dysfunction through attenuating oxidative stress and modulating microglia M1/M2 polarization.PeerJ. 2024 Nov 15;12:e18507. doi: 10.7717/peerj.18507. eCollection 2024. PeerJ. 2024. PMID: 39559329 Free PMC article.
-
Therapeutic potential of natural coumarins in autoimmune diseases with underlying mechanisms.Front Immunol. 2024 Oct 31;15:1432846. doi: 10.3389/fimmu.2024.1432846. eCollection 2024. Front Immunol. 2024. PMID: 39544933 Free PMC article. Review.
-
Hemophagocytic lymphohistiocytosis: current treatment advances, emerging _targeted therapy and underlying mechanisms.J Hematol Oncol. 2024 Nov 7;17(1):106. doi: 10.1186/s13045-024-01621-x. J Hematol Oncol. 2024. PMID: 39511607 Free PMC article. Review.
-
Tumour Immunotherapy and Applications of Immunological Products: A Review of Literature.J Immunol Res. 2024 Oct 24;2024:8481761. doi: 10.1155/2024/8481761. eCollection 2024. J Immunol Res. 2024. PMID: 39483536 Free PMC article. Review.
References
-
- Hacein-Bey-Abina S, Le Deist F, Carlier F, et al. Sustained correction of X-linked severe combined immunodeficiency by ex vivo gene therapy. N Engl J Med. 2002;346:1185–93. - PubMed
-
- Hacein-Bey-Abina S, von Kalle C, Schmidt M, et al. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003;348:255–6. - PubMed
-
- Minegishi Y, Saito M, Tsuchiya S, et al. Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. Nature. 2007;448:1058–62. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources